Five year retrospective study of mortality in systemic inflammatory rheumatologic disorders
Keywords:Disease activity, Inflammatory systemic rheumatologic diseases, Infection, Mortality
Background: Inflammatory systemic rheumatologic disorders are responsible for significant morbidity and premature deaths. The present study was done to assess causes of mortality in these patients.
Methods: In the retrospective study, the death records of patients with inflammatory rheumatologic illnesses from January 2012 to January 2017 were studied. The demographic details, disease activity, organ involvement, treatment received and evidence of infection were noted.
Results: 50 records were analyzed (25 systemic lupus erythematosus (SLE), 13 rheumatoid arthritis (RA), four immune myositis, three systemic sclerosis (SS), two takayasu’s arteritis (TA), two ankylosing spondylitis (AS) and one granulomatosis with polyangiitis (GPA)). The me an age of death was 39.94 years. Sixteen patients had disease related organ damage, 17 had active disease. Infection was present in 31 patients (gram negative organisms most commonly isolated), being the major contributor of mortality. Only two patients succumbed to acute coronary syndrome.
Conclusions: Infection, disease activity and organ damage due to the disease are the major contributors to of death in hospitalized patients with inflammatory rheumatological disorders.
Gustafsson JT, Simard JF, Gunnarsson I. Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. Arthritis Res Ther. 2012;14(2):46-9.
Faurschou M, Mellemkjaer L, Starklint H, Kamper A, Tarp U, Voss A, et al. High risk of ischemic heart disease in patients with lupus nephritis. J Rheumatol. 2011;38(11):2400-5.
Butt S, Jeppesen J, Fuchs C, Mogensen M, Engelhart M, Pedersen C. Trends in incidence, mortality, and causes of death associated with systemic sclerosis in Denmark between 1995 and 2015: a nationwide cohort study. BMC Rheumatol. 2018;2:36-9.
Van DHJ, Boshuizen HC, Roorda LD, Tijhuis GJ, Nurmohamed MT, Bos GA, et al. Mortality in patients with rheumatoid arthritis: a 15-year prospective cohort study. Rheumatol Int. 2017;37(4):487-93.
Bronner IM, Van MFG, Visser M, Kalmijn S, Venrooij WJ, Voskuyl AE. Long-term outcome in polymyositis and dermatomyositis. Curr Rheumatol Rep. 2012;14(3):275-85.
Avouac J, Amrouche F, Meune C, Rey G, Kahan A, Allanore Y. Mortality profile of patients with rheumatoid arthritis in France and its change in 10 years. Arthr Rheumat. 2017;46(5):537-43.
Salmon JE, Roman MJ. Accelerated atherosclerosis in systemic lupus erythematosus: implications for patient management. Curr Opin Rheumatol. 2001;13(5):341-4.
Nieves CE, Izmirly PM. Mortality in systemic lupus erythematosus: an updated review. Curr Rheumatol Rep. 2016;18(4):21-7.
Petri M, Gutthann PS, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med. 1992;93:513-9.
Nikpour M, Baron M. Mortality in systemic sclerosis: lessons learned from population-based and observational cohort studies. 2014;26(2):131-7.
Park SJ, Kim HJ, Park H. Incidence, prevalence, mortality and causes of death in takayasu arteritis in korea a nationwide, population-based study. Int J Cardiol. 2017;235:100-4.
Wang Z, Wang Y, Zhu R, Tian X, Xu D, Wang Q, et al. Long-term survival and death causes of systemic lupus erythematosus in China: a systemic review of observational studies. Med Baltimore. 2015;94:79-84.
Jeong SJ, Choi H, Lee HS, Han SH, Chin BS, Baek JH, et al. Incidence and risk factors of infection in a single cohort of 110 adults with systemic lupus erythematosus. Scand J Infect Dis. 2009;41:268-74.
Teh CL, Wan SA, Ling GR. Severe infections in systemic lupus erythematosus: disease pattern and predictors of infection-related mortality. Clin Rheumatol. 2018;37(8):2081-6.
Luqmani R, Suppiah R, Edwards CJ, Phillip R, Maskell J, Culliford D. Mortality in wegener’s granulomatosis: a bimodal pattern. Rheumatol. 2011;50(4):697-702.
Goldblatt F, Chambers S, Rahman A, Isenberg DA. Serious infections in British patients with systemic lupus erythematosus: hospitalizations and mortality. Lupus. 2009;18(8):682-9.
Danza A, Irastorza RG. Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies. Clin Rheumatol. 2018;37(8):2081-6.
Erdozain JG, Irastorza RG, Egurbide MV, Berriotxoa MA, Aguirre C. High risk of tuberculosis in systemic lupus erythematosus? Lupus. 2006;15(4):232-5.
Franco MD, Lucchino B, Spaziante M. Lung infections in systemic rheumatic disease: focus on opportunistic infections. Int J Mol Sci. 2017;18(2):293-6.
Murray S, Schmajuk G, Trupin L. Infection is the leading cause of hospital mortality in patients with dermatomyositis/polymyositis: data from a population- based study. Arthritis Care Res. 2015;67(5):673-80.
Feldman CH, Hiraki LT, Winkelmayer WC, Marty FM, Franklin JM, Kim SC. Serious infections among adult medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis. Arthritis Rheumatol. 2015;67(6):1577-85.
Souza DC, Santo AH, Sato EI. Mortality profile related to systemic lupus erythematosus: a multiple cause-of-death analysis. J Rheumatol. 2012;39(3):496-503.
Bharath G, Kumar P, Makkar N, Singla P, Soneja M, Biswas A, et al. Mortality in systemic lupus erythematosus at a teaching hospital in India: a 5-year retrospective study. Rheumatol. 2019;8(7):2511-5.
Sharma A, Shamanna SB, Kumar S, Wanchu A, Bambery P, Singh S, et al. Causes of mortality among inpatients with systemic lupus erythematosus in a tertiary care hospital in North India over a 10-year period. Lupus. 2013;22(2):216-22.
Piraquive OV, Aristizábal NI, Cañas CA, Tobón GJ. Mortality in systemic lupus erythematosus: causes, predictors and interventions. Expert Rev Clin Immunol. 2018;14(12):1043-53.
Bertsias G, Ioannidis JP, Boletis J. EULAR recommendations for the management of systemic lupus erythematosus report of a task force of the EULAR. Expert Rev Clin Immunol. 2018;14(12):1043-53.
Bakland G, Gran JT, Nossent JC. Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis. 2011;70(11):1921-5.
Listing J, Kekow J, Manger B, Burmester GR, Pattloch D, Zink A, et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. Ann Rheum Dis. 2015;74:415-21.
Aznar CP, Pla´ FV, Vilella TC, Garriga EG, Grau CM, Casals RM, et al. Registry of the Spanish network for systemic sclerosis survival, prognostic factors, and causes of death. Medicine. 2015;94(43):77-83.